Inflammation

In a prospective cohort study among ~28,000 initially healthy US women, a single combined measurement of hs-CRP, LDL-c, and Lp(a) levels predicted incident MACE over the next 30 years.

This summary is based on the publication of Ridker PM, Moorthy MV, Cook NR, et al. - Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. N Engl J Med. 2024 Aug 31 ...

In an analysis of 28 cohorts, hs-cTnI, hs-cTnT, NT-proBNP, BNP, and hs-CRP were predictors of mortality and CV events. Addition of these biomarkers to conventional risk factors resulted in a better risk prediction of HF, mortality, and, to a lesser extent, ASCVD.

This summary is based on the publication of Neumann JT, Twerenbold R, Weimann J, et al. - Prognostic Value of Cardiovascular Biomarkers in the Population. JAMA. 2024 Jun 11;331(22):1898-1909. doi: 10....

In a Dutch self-controlled case series study, there was a 6-fold higher incidence of acute MI in the first week after influenza virus infection compared with 1 year before and 1 year after, especially in individuals with no prior hospitalization for coronary artery disease.

This summary is based on the publication of De Boer AR, Riezebos-Brilman A, van Hout D, et al. - Influenza Infection and Acute Myocardial Infarction. NEJM Evid. 2024 Jul;3(7):EVIDoa2300361. doi: 10.10...

An international multidisciplinary task force published updated consensus recommendations for the management of diabetes, cardiorenal, and/or metabolic (DCRM) diseases.

An international volunteer task force comprising experts in cardiology, nephrology, endocrinology and primary care medicine developed the DCRM 2.0 Practice Recommendations, updating and expanding the ...

EAS 2024 – In an analysis of SELECT among CVD patients with overweight or obesity, baseline hsCRP was a prognostic biomarker for subsequent MACE. Semaglutide reduced hsCRP levels early in SELECT prior to major weight loss.

This summary is based on the presentation of Jorge Plutzky, MD (Boston, MA, US) at the EAS Congress 2024 – Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or ...

ESC Congress 2023 A prespecified analysis of the CLEAR Outcomes trial showed that bempedoic acid reduced the total incidence of the composite outcome of CV death, MI, stroke, or coronary revascularization by 20%.

Presented at the ESC Congress 2023 by:Stephen Nicholls, MD - Melbourne...

ESC Congress 2023 The COP-AF trial showed that colchicine does not lower the incidence of clinically important perioperative AF or myocardial injury in patients undergoing major non-cardiac thoracic surgery.

Presented at the ESC Congress 2023 by: David Conen, MD - Hamilto...

The U.S. Food and Drug Administration (FDA) has approved the use of colchicine, an anti-inflammatory drug, for the treatment of adult patients with established ASCVD or multiple CVD risk factors.

The FDA has approved colchicine as the first anti-inflammatory drug for the treatment of CVD. Colchicine is indicated to reduce the risk of MI, stroke, coronary revascularizat...

In a pooled post hoc analysis of DAPA-HF and DELIVER the benefits of dapagliflozin were independent of gout status in patients with HF across the spectrum of LVEF.

A secondary analysis of the RESCUE trial investigated whether IL-6 inhibition with ziltivekimab, a novel therapeutic monoclonal antibody against IL-6, changes the neutrophil-lymphocyte ratio (NLR) in patients with CKD and elevated hsCRP.

In this post hoc analysis of the ODYSSEY OUTCOMES trial, the authors demonstrated that the beneficial effects of alirocumab on Lp(a)-associated risk of CV events in patients with ACS are modified by hsCRP.

In a secondary biomarker analysis of the CLEAR Harmony trial, bempedoic acid lowered levels of LDL-c and hs-CRP, but not fibrinogen or IL-6, compared with placebo in patients with ASCVD and/or heterozygous familial hypercholesterolemia (HeFH) who had residual inflammatory risk.

ACC.23 In a collaborative analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials, hs-CRP was a better predictor of future MACE, CV death, and all-cause mortality than LDL-c in statin-treated patients with, or at high risk of, atherosclerotic disease.

Presented at the ACC.23 by:...

ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.

Presented at the ACC.23 by: Prof. Steven Nissen, MD - Cleveland, OH, ...

Circulating biomarkers of myocardial injury, hemodynamic stress, systemic inflammation or renal function are related to adverse CV outcomes in patients with HFrEF. Do these biomarkers identify the treatment effect of vericiguat beyond clinical factors and NT-proBNP in the VICTORIA trial?

In a REDUCE-IT substudy, icosapent ethyl had little to no effect on biomarkers associated with atherosclerotic disease, such as IL-1β, IL-6, oxidized LDL-c, and Lp(a). However, mineral oil increased these levels.